secwatch.observer — SEC 8-K summary
======================================

Issuer:     CITIUS ONCOLOGY, INC. (CTOR)
CIK:        0001851484
Form:       8-K
Filed at:   2025-12-01T23:59:59+00:00
Accession:  0001213900-25-116764
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Citius Oncology launches LYMPHIR, first commercial product, for CTCL
--------------------------------------------------------------------

- LYMPHIR (denileukin diftitox-cxdl) now available nationwide via specialty distributors.
- Phase 3 pivotal study: 36.2% ORR, median time to response 1.4 months, no cumulative toxicity.
- Entering U.S. market estimated >$400M; permanent J-code J9161 and NCCN Category 2A inclusion.
- Ex-U.S. distribution pact with Integris Pharma for 12 Southern European/Balkan markets.
- Company holds exclusive rights to all markets except India, Japan, and parts of Asia.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1851484/000121390025116764/0001213900-25-116764-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1851484/000121390025116764/ea0267560-8k_citius.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-116764

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer